MX2017003216A - Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. - Google Patents

Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.

Info

Publication number
MX2017003216A
MX2017003216A MX2017003216A MX2017003216A MX2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A
Authority
MX
Mexico
Prior art keywords
antagonists
progression
psoriatic arthritis
structural damage
inhibit
Prior art date
Application number
MX2017003216A
Other languages
English (en)
Spanish (es)
Inventor
Mpofu Shephard
Richards Hanno
LIGOZIO Gregory
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017003216(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017003216A publication Critical patent/MX2017003216A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
MX2017003216A 2014-09-10 2015-09-08 Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. MX2017003216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
MX2017003216A true MX2017003216A (es) 2017-05-23

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003216A MX2017003216A (es) 2014-09-10 2015-09-08 Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.

Country Status (22)

Country Link
US (2) US11278618B2 (cg-RX-API-DMAC7.html)
EP (2) EP4406969A3 (cg-RX-API-DMAC7.html)
JP (4) JP2017528465A (cg-RX-API-DMAC7.html)
KR (2) KR20170045240A (cg-RX-API-DMAC7.html)
CN (4) CN113069542A (cg-RX-API-DMAC7.html)
AU (2) AU2015313827C1 (cg-RX-API-DMAC7.html)
BR (1) BR112017003332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2960754A1 (cg-RX-API-DMAC7.html)
DK (1) DK3191120T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981697T3 (cg-RX-API-DMAC7.html)
FI (1) FI3191120T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240921T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067081T2 (cg-RX-API-DMAC7.html)
LT (1) LT3191120T (cg-RX-API-DMAC7.html)
MX (1) MX2017003216A (cg-RX-API-DMAC7.html)
PL (1) PL3191120T3 (cg-RX-API-DMAC7.html)
PT (1) PT3191120T (cg-RX-API-DMAC7.html)
RS (1) RS65851B1 (cg-RX-API-DMAC7.html)
RU (1) RU2697383C2 (cg-RX-API-DMAC7.html)
SI (1) SI3191120T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400285T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016038538A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3191120T3 (da) * 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt
RU2754683C2 (ru) 2015-10-27 2021-09-06 Юсб Биофарма Срл Способы лечения с использованием анти-il-17a антител
TW201842933A (zh) * 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
WO2019040230A1 (en) * 2017-08-23 2019-02-28 Eli Lilly And Company TREATMENT OF GENITAL PSORIASIS
US20210179702A1 (en) * 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
MX2021014953A (es) * 2019-06-04 2022-01-24 Janssen Biotech Inc Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23.
KR102576258B1 (ko) 2019-12-05 2023-09-11 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20100239590A1 (en) 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
WO2010034443A1 (en) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof
LT2625199T (lt) * 2010-10-08 2018-03-12 Novartis Ag Psoriazės gydymo būdai panaudojant il-17 antagonistus
CN104800844A (zh) * 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
US20150064193A1 (en) * 2011-11-21 2015-03-05 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
DK3191120T3 (da) * 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt

Also Published As

Publication number Publication date
FI3191120T3 (fi) 2024-07-10
KR20170045240A (ko) 2017-04-26
KR20230170796A (ko) 2023-12-19
RU2017107501A (ru) 2018-10-10
SMT202400285T1 (it) 2024-09-16
JP2025024104A (ja) 2025-02-19
RU2697383C2 (ru) 2019-08-13
PL3191120T3 (pl) 2024-08-26
EP4406969A3 (en) 2024-11-27
US11278618B2 (en) 2022-03-22
CN107073110A (zh) 2017-08-18
CA2960754A1 (en) 2016-03-17
AU2015313827A1 (en) 2017-02-16
JP2021152021A (ja) 2021-09-30
JP2017528465A (ja) 2017-09-28
CN113069542A (zh) 2021-07-06
CN115957326A (zh) 2023-04-14
EP3191120A1 (en) 2017-07-19
AU2018201410A1 (en) 2018-03-22
JP2023109973A (ja) 2023-08-08
SI3191120T1 (sl) 2024-10-30
RU2017107501A3 (cg-RX-API-DMAC7.html) 2019-03-12
JP7591092B2 (ja) 2024-11-27
AU2015313827B2 (en) 2018-02-15
US20220313818A1 (en) 2022-10-06
HRP20240921T1 (hr) 2024-10-11
US20170281762A1 (en) 2017-10-05
AU2015313827C1 (en) 2018-08-30
DK3191120T3 (da) 2024-07-15
PT3191120T (pt) 2024-07-16
ES2981697T3 (es) 2024-10-10
BR112017003332A2 (pt) 2017-11-28
LT3191120T (lt) 2024-07-25
WO2016038538A1 (en) 2016-03-17
JP7288927B2 (ja) 2023-06-08
RS65851B1 (sr) 2024-09-30
EP4406969A2 (en) 2024-07-31
HUE067081T2 (hu) 2024-09-28
CN115944734A (zh) 2023-04-11
EP3191120B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
NZ737399A (en) Ccr2 modulators
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
MX378273B (es) Compuestos activos hacia bromodominios.
MX2013009679A (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
PH12016500094A1 (en) Autotaxin inhibitors
EA201691582A1 (ru) Новые фармацевтические препараты
HUE049341T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
EA201590359A1 (ru) Лечение ревматоидного артрита
TW201613864A (en) Novel compounds
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2021010472A (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX382918B (es) Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.